EdgarLookup

ZyVersa Therapeutics, Inc. — Insider Transactions

Form 4 filings by directors, officers, and 10%+ shareholders

SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.

Overview All Filings Annual Quarterly Insiders
Insider Title Type Shares Price Value Owns After Date
Wolfe Peter Chief Financial Officer Award / Grant 3,000 $2.88 $8,640 44,585 Dec 16, 2022
INCON Co., Ltd. Award / Grant 1,497,199 1,497,199 Dec 12, 2022
Wolfe Peter Chief Financial Officer Award / Grant 41,585 41,585 Dec 12, 2022
LaBella Nicholas A. Jr. Chief Scientific Officer Award / Grant 18,094 18,094 Dec 12, 2022
Glover Stephen C. Chief Executive Officer Award / Grant 43,847 43,847 Dec 12, 2022
O'Connor Daniel J. Other 1,377,598 1,377,598 Dec 12, 2022
A.G.P. / ALLIANCE GLOBAL PARTNERS CORP. Other 3,427 446,843 Mar 8, 2022
A.G.P. / ALLIANCE GLOBAL PARTNERS CORP. Other 49,730 450,270 Feb 3, 2022
Larkspur Health LLC Other 236,273 236,273 Jan 6, 2022
O'Connor Daniel J. Chief Executive Officer Other 42,005 42,005 Jan 6, 2022
Briones David S. Chief Financial Officer Other 10,752 10,752 Jan 6, 2022